{"id":52551,"name":"CAPTURA BIOPHARMA","slug":"captura-biopharma","state":"AR","country":"United States of America","description":"Captura is developing an orally administered MCM for radionuclide contamination.","totalSpending":66000,"filings":17,"yearlySpending":[{"year":2022,"income":60000},{"year":2023,"income":6000},{"year":2024,"income":0},{"year":2025,"income":0}],"issues":[{"code":"DEF","display":"Defense"},{"code":"HCR","display":"Health Issues"},{"code":"DIS","display":"Disaster Planning/Emergencies"}],"firms":["HORIZONS GLOBAL SOLUTIONS LLC"],"lobbyists":["DAVID LASSETER","JULIE LASSETER","STEPHEN BOYD"],"govEntities":["Defense, Dept of (DOD)","Defense Threat Reduction Agency (DTRA)","HOUSE OF REPRESENTATIVES","Army, Dept of (Other)","SENATE"],"sampleDescriptions":["Support Captura Biopharma in educating executive and legislative branch officials and personnel on the current medical countermeasure limitations of existing radionuclide and heavy metal exposure medi","Support Captura Biopharma in educating executive and legislative branch officials and personnel on the current medical countermeasure limitations of existing radionuclide and heavy metal exposure medi","Response capabilities related to internal radionuclide contamination.","Response capabilities related to internal radionuclide contamination.","FY2024 NDAA; FY2024 Defense Appropriations"]}